--Abstracts Released on ASCO.org--
NEW YORK--(BUSINESS WIRE)--
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that Douglas J.
Schwartzentruber, M.D., FACS, of the Indiana University Health Goshen
Center for Cancer Care, will present clinical results from the
first-ever treatment demonstrating control by an orally administered
small molecule over the transgene-encoded expression of a therapeutic
anti-cancer protein in humans, at the 2011 Annual Meeting of the
American Society of Clinical Oncology (ASCO) being held June 3 - 7 in
Chicago, IL. Results from the Phase Ib study of DC-RTS-IL-12 will be
presented during the Developmental Therapeutics - Clinical Pharmacology
and Immunotherapy Poster Session on Monday, June 6th from 8:00 am to
12:00 pm CT at McCormick Place, Hall A in Chicago, IL, in a poster
titled: "Immunotherapy of advanced melanoma by intra-tumoral injections
of autologous, purified dendritic cells transduced with gene construct
of interleukin-12, with dose-dependent expression under the control of
an oral activator ligand" (Poster # 1A).
The study abstract (#2540), released yesterday on www.ASCO.org,
concludes that this Phase I trial in patients with advanced melanoma has
confirmed key findings from mouse tumor models.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a biopharmaceutical company engaged in the
development and commercialization of a diverse portfolio of cancer
therapeutics. The Company is currently focused on several clinical
programs.
Palifosfamide (Zymafos™ or ZIO-201) is a novel DNA cross-linker in class
with bendamustine, ifosfamide, and cyclophosphamide. ZIOPHARM is
currently enrolling patients in a randomized, double-blinded,
placebo-controlled Phase III trial with palifosfamide administered
intravenously for the treatment of metastatic soft tissue sarcoma in the
front-line setting. The company is also currently conducting a Phase I
intravenous study of palifosfamide in combination with standard of care
for addressing small cell lung cancer likely in an adaptive potentially
pivotal trial and an oral form of the drug for treatment of solid tumors
is currently in the advanced preclinical stage of development.
Darinaparsin (Zinapar™ or ZIO-101) is a novel mitochondrial-targeted
agent (organic arsenic) being developed intravenously for the treatment
of relapsed peripheral T-cell lymphoma likely with an adaptive
potentially pivotal study expected to begin in late 2011. An oral form
is in a Phase I trial in solid tumors.
Indibulin (Zybulin™ or ZIO-301) is a novel, oral tubulin binding agent
that is expected to have several potential benefits including oral
dosing, application in multi-drug resistant tumors, no neuropathy and a
quite tolerable toxicity profile. It is currently being studied in Phase
I in metastatic breast cancer with an expected substitution of a
modified dosage form for simpler dosage administration.
ZIOPHARM is also pursuing the development of novel DNA-based
therapeutics in the field of cancer pursuant to an exclusive channel
partnership with Intrexon Corporation. The partnership includes two
existing clinical-stage product candidates, the first of which is in a
Phase Ib study and the second is currently the subject of an
Investigational New Drug (IND) application filed with the U.S. Food and
Drug Administration.
ZIOPHARM's operations are located in Boston, MA and Germantown, MD with
an executive office in New York City. Further information about ZIOPHARM
may be found at www.ziopharm.com.
ZIOP-G
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements for ZIOPHARM
Oncology, Inc. that involve risks and uncertainties that could cause
ZIOPHARM Oncology's actual results to differ materially from the
anticipated results and expectations expressed in these forward-looking
statements. These statements are based on current expectations,
forecasts and assumptions that are subject to risks and uncertainties,
which could cause actual outcomes and results to differ materially from
these statements. Among other things, there can be no assurance that any
of ZIOPHARM Oncology's development efforts relating to its product
candidates will be successful, or such product candidates will be
successfully commercialized. Other risks that affect forward-looking
information contained in this press release include the possibility of
being unable to obtain regulatory approval of ZIOPHARM Oncology's
product candidates, the risk that the results of clinical trials may not
support ZIOPHARM Oncology's claims, the risk that pre-clinical or
clinical trials will not proceed on schedules that are consistent with
ZIOPHARM Oncology's current expectations or at all, risks related to
ZIOPHARM Oncology's ability to protect its intellectual property and its
reliance on third parties to develop its product candidates, risks
related to the sufficiency of existing capital reserves to fund
continued operations for a particular amount of time and uncertainties
regarding ZIOPHARM Oncology's ability to obtain additional financing to
support its operations thereafter, as well as other risks regarding
ZIOPHARM Oncology that are discussed under the heading "Risk Factors" in
ZIOPHARM Oncology's filings with the United States Securities and
Exchange Commission. Forward-looking statements can be identified by the
use of words such as "may," "will," "intend," "should," "could," "can,"
"would," "expect," "believe," "estimate," " predict," "potential,"
"plan," "is designed to," "target" and similar expressions. ZIOPHARM
Oncology assumes no obligation to update these forward-looking
statements, except as required by law.
For ZIOPHARM:
ZIOPHARM Oncology, Inc.
Tyler Cook,
617-259-1982
tcook@ziopharm.com
or
Media:
Argot
Partners
David Pitts, 212-600-1902
david@argotpartners.com
Source: ZIOPHARM Oncology, Inc.
News Provided by Acquire Media
